{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005094","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.036770+00:00","generated_at":"2026-06-18T22:18:56.257193+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Crinetics reports Q4 2022 net loss of $45M; paltusotine Phase 3 data expected 3Q23 and 1Q24","bullets":["Net loss $45.0M for Q4 2022 vs $30.8M in Q4 2021; full-year net loss $163.9M vs $107.6M.","R&D expenses $37.0M in Q4 2022, up from $24.6M; full-year $130.2M vs $84.3M.","Cash, equivalents, and investments $334.4M as of Dec 31, 2022; company expects runway through 2024.","Paltusotine Phase 3 PATHFNDR-1 topline data expected 3Q23; PATHFNDR-2 data now expected 1Q24.","NDA submission for paltusotine in acromegaly planned for 2024 pending positive Phase 3 results."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005094","json":"https://secwatch.observer/filing/0000950170-23-005094.json","markdown":"https://secwatch.observer/filing/0000950170-23-005094.md","text":"https://secwatch.observer/filing/0000950170-23-005094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/0000950170-23-005094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/crnx-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:18:56.257193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d0c5d65a3c77d30a32aba09194579355e06c178","claim":"Crinetics Pharmaceuticals, Inc. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"SAN DIEGO – February 28, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/0000950170-23-005094-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"844d600231bb77d24042f4d791c0f947238d5cae","claim":"Crinetics Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"SAN DIEGO – February 28, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/0000950170-23-005094-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}